Prometic is a biopharmaceutical company based in Laval, Quebec, Canada. The firm was run by Pierre Laurin, chairman and CEO for 24 years. Since April 2019, it is now managed by Prometic CEO Kenneth Galbraith.
ProMetic develops therapeutics for unsatisfied clinical conditions in the field of hematology, oncology and autoimmune diseases.
ProMetic has also developed a proven technology to isolate and purify proteins. This technology is used by over 40 multinationals for the manufacturing of their own therapeutics: 12 of these companies have their respective drugs approved by the FDA / EMEA
The firm also has offices in Isle of Man, UK and Rockland, Maryland, USA.
Since filming, M. Laurin has left the company in December 2018.
The case was filmed in 2016 in Laval, Quebec, Canada at Prometic’s Canadian facilities.
Course Content
Biopharma, Orphan Drugs, IP, Multinationals, Pharmaceutical industry, Biotech, complex drugs, human plasma, protein isolation, bringing new drugs to market, commercializing drugs, Laval, university research spinoffs, velcro business model, going public, IPO, joint ventures, international partnerships, American Red Cross, climate change disruption, royalty streams, doing business with governments in emerging markets, managing growth.
Technical Specs
Production date: 2017
Participant:
Pierre Laurin, former Prometic CEO
Special thanks:
Frederic Dumais, former Prometic Senior Director
Executive Producers
Dr Hamid Etemad, McGill University
Hamed Motaghi, Université du Québec en Outaouais
Producer
Thierry Harris, Cartouche Media
Creative Director
Melissa Gendron, Cartouche Media
Course Reviews
No Reviews found for this course.